Professor, Medicine, University of Pittsburgh School of Medicine
Rheumatology
Dr. Larry W. Moreland, MD
|
|
Give Review
Dr. Larry W. Moreland works in the field of Rheumatology. He graduated from University of Alabama Medical Center. University of Alabama Medical Center has a rank of 37 in research and a 17 in primary care He has 4 awards "CMS Meaningful Use Stage 1 Certification", "Elected Member", "Fellow" and "Fellow (FACR)". Larry Moreland is a published doctor and has 75 publications published. The lastest was: 'Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.' He is registered with Medicare and accepts Medicare payments.
Publications
- Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.
- Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid Arthritis.
- A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility.
- Comprehensive appraisal of MRI findings in sustained RA remission: Sub-study of the TEAR trial.
- Induction Therapy with Combination TNF Inhibitor and Methotrexate in Early Rheumatoid Arthritis.
- Socioeconomic disparities in the health of African-Americans with rheumatoid Arthritis from the Southeastern USA.
- Determinants of Mortality Among Postmenopausal Women in the Women's Health Initiative Who Report Rheumatoid Arthritis.
- Genetics of rheumatoid Arthritis contributes to biology and drug discovery.
- Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid Arthritis.
- Associations of Alcohol Use with Radiographic Disease Progression in African Americans with Recent-onset Rheumatoid Arthritis.
- Comparison of the Disease Activity Score Using Erythrocyte Sedimentation Rate and C-reactive Protein in African Americans with Rheumatoid Arthritis.
- Complementary and alternative medicine use in african-americans with rheumatoid Arthritis.
- Validation of methotrexate-first strategy in early poor prognosis rheumatoid Arthritis: Results from a randomized, double-blind, 2-year trial.
- Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge.
- Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial.
- Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid Arthritis: results from the treatment of early aggressive rheumatoid Arthritis ...
- Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Tria...
- Changes in lipoproteins associated with treatment with methotrexate or combination therapy in early rheumatoid Arthritis: Results from the TEAR trial.
- Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis.
- Phenome-Wide Association Study (PheWAS) for Detection of Pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network.
- A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid Arthritis: The treatment of earl...
- Interactions of cigarette smoking with NAT2 polymorphisms impact rheumatoid Arthritis risk in African Americans.
- Cost-effectiveness of biologics compared with disease-modifying antirheumatic drugs in rheumatoid Arthritis.
- Inhibition of spleen tyrosine kinase for rheumatoid Arthritis.
- JAK inhibition in rheumatoid Arthritis.
- Most common single-nucleotide polymorphisms associated with rheumatoid Arthritis in persons of European ancestry confer risk of rheumatoid Arthritis in African Americans.
- Associations of cigarette smoking with rheumatoid Arthritis in African Americans.
- Most common SNPs associated with rheumatoid Arthritis in subjects of European ancestry confer risk of rheumatoid Arthritis in African-Americans.
- A functional RANKL polymorphism associated with younger age at onset of rheumatoid Arthritis.
- 2010 Rheumatoid Arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
- Rheumatoid Arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.
- Radiographic severity of rheumatoid Arthritis in African Americans: results from a multicenter observational study.
- Retraction: an African ancestry-specific allele of CTLA4 confers protection against rheumatoid Arthritis in African Americans.
- Cytokines as targets for anti-inflammatory agents.
- Systemic nonarticular manifestations of rheumatoid Arthritis: focus on inflammatory mechanisms.
- Tocilizumab versus methotrexate in moderate to severe rheumatoid Arthritis.
- Certolizumab pegol in active rheumatoid Arthritis.
- Methotrexate versus combination methotrexate and etanercept for rheumatoid Arthritis.
- Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.
- Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active Rheumatoid...
- Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid Arthritis and the quest for improved sensitivity and predictive value.
- REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid Arthritis.
- Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
- An African ancestry-specific allele of CTLA4 confers protection against rheumatoid Arthritis in African Americans.
- Results of a two-year followup study of patients with rheumatoid Arthritis who received a combination of abatacept and methotrexate.
- The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid Arthritis in African Americans through European genetic admixture.
- Psoriatic Arthritis: current concepts on pathogenesis-oriented therapeutic options.
- Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in African Americans with early rheumatoid Arthritis.
- Effects of abatacept in patients with methotrexate-resistant active rheumatoid Arthritis: a randomized trial.
- Effect of etanercept on fatigue in patients with recent or established rheumatoid Arthritis.
- Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoArthritis.
- Febuxostat--treatment for hyperuricemia and Gout?
- Validation of American College of Rheumatology classification criteria for knee osteoArthritis using arthroscopically defined cartilage damage scores.
- Treatment of rheumatoid Arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controll...
- Effects of doxycycline on progression of osteoArthritis: results of a randomized, placebo-controlled, double-blind trial.
- Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoArthritis drug.
- The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid Arthritis with methotrexate or etanercept.
- Effects of prasterone on Disease activity and symptoms in women with active systemic lupus erythematosus.
- Biologic therapies on the horizon for rheumatoid Arthritis.
- A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid Arthritis: a pilot study [ISRCTN03626626].
- Treatment of rheumatoid Arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.
- Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid Arthritis...
- Upcoming biologic agents for the treatment of rheumatic Diseases.
- Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid Arthritis in patients taking concomitant methotrexate: ...
- Glucocorticoids and rheumatoid Arthritis: back to the future?
- Efficacy of tacrolimus in rheumatoid Arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
- High-resolution ultrasound for the study of target joints in rheumatoid Arthritis.
- Etanercept versus methotrexate in patients with early rheumatoid Arthritis: two-year radiographic and clinical outcomes.
- Costimulatory blockade in patients with rheumatoid Arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eig...
- Hydroxychloroquine concentration-response relationships in patients with rheumatoid Arthritis.
- Treatment of rheumatoid Arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week...
- Genetic influences on rheumatoid Arthritis in African Americans.
- The Use of Methotrexate Perioperatively in Patients with Rheumatoid Arthritis Undergoing Major Joint Replacement Surgery: Will We Ever Have Consensus about Its Use?
- Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene.
Schools
West Virginia University
Procedures Preformed
- Joint Drainage
- Steroid Injection
- Trigger Point Injection
- Viscosupplementation With Hyaluronate
Conditions Treated
- Achilles Tendinitis
- Ankylosing Spondylitis
- Arthritis
- Behçet's Disease
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
- Fellow
- Fellow (FACR)
Education
-
University of Alabama Medical Center -
West Virginia University -
West Virginia University School of Medicine
Hospital
-
UPMC Presbyterian Shadyside -
UPMC Passavant
Drug Facts
| NPI NUMBER | 1720019334 | |
| NPPES Provider LastName | MORELAND | |
| NPPES Provider FirstName | LARRY | |
| NPPES Provider ZIPCode | 152610001 | |
| NPPES Provider State | PA | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 1840.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 545.0 | |
| Percent Opioid Claims | 29.62 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720019334 |
| Last Name Of The Provider | MORELAND |
| First Name Of The Provider | LARRY |
| View All |
Similar Doctors
|
|
Dr. Thaddeus A. Osial Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sherwood M. Chetlin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Helfrich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth N. Gold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine Peoples, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chester V. Oddis, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daniel L. Delo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Burton H. Pollock, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bertrand L. Stolzer, MD |
|
|
Dr. Jeremy S. Tilstra, MD
This Doctor is OpenDoctor Recommended.
|